deltatrials
Recruiting PHASE3 INTERVENTIONAL 3-arm NCT04772079

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis

A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Sponsor: Bristol-Myers Squibb

Conditions Plaque Psoriasis
Interventions Deucravacitinib Placebo matching deucravacitinib
Updated 36 times since 2021 Last updated: Sep 24, 2025 Started: Mar 23, 2021 Primary completion: Jan 1, 2029 Completion: Sep 8, 2033
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Plaque Psoriasis and is currently actively recruiting participants. Bristol-Myers Squibb leads this study, which shows 36 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Jun 2022 · 4 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Nov 2023 · 2 months · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Dec 2024 · 30 days · monthly snapshot~Dec 2024 – ~Jan 2025 · 31 days · monthly snapshot~Jan 2025 – ~Mar 2025 · 59 days · monthly snapshot~Mar 2025 – ~May 2025 · 2 months · monthly snapshot~May 2025 – ~Jun 2025 · 31 days · monthly snapshot~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshot~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 10 months · monthly snapshot

Change History

36 versions recorded

  1. Oct 2025 — Present [monthly]

    Recruiting PHASE3

  2. Sep 2025 — Oct 2025 [monthly]

    Recruiting PHASE3

  3. Aug 2025 — Sep 2025 [monthly]

    Recruiting PHASE3

  4. Jul 2025 — Aug 2025 [monthly]

    Recruiting PHASE3

  5. Jun 2025 — Jul 2025 [monthly]

    Recruiting PHASE3

▶ Show 31 earlier versions

  1. May 2025 — Jun 2025 [monthly]

    Recruiting PHASE3

  2. Mar 2025 — May 2025 [monthly]

    Recruiting PHASE3

  3. Jan 2025 — Mar 2025 [monthly]

    Recruiting PHASE3

  4. Dec 2024 — Jan 2025 [monthly]

    Recruiting PHASE3

  5. Nov 2024 — Dec 2024 [monthly]

    Recruiting PHASE3

  6. Oct 2024 — Nov 2024 [monthly]

    Recruiting PHASE3

  7. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE3

  8. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  9. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE3

  10. Mar 2024 — Jul 2024 [monthly]

    Recruiting PHASE3

  11. Jan 2024 — Mar 2024 [monthly]

    Recruiting PHASE3

  12. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE3

  13. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE3

  14. Sep 2023 — Nov 2023 [monthly]

    Recruiting PHASE3

  15. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE3

  16. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE3

  17. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE3

  18. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE3

  19. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE3

  20. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE3

  21. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE3

  22. Dec 2022 — Feb 2023 [monthly]

    Recruiting PHASE3

  23. Sep 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

  24. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  25. Feb 2022 — Jun 2022 [monthly]

    Recruiting PHASE3

  26. Dec 2021 — Feb 2022 [monthly]

    Recruiting PHASE3

  27. Oct 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  28. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  29. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  30. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  31. Mar 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alicante, Spain , Barakaldo, Spain , Berlin, Germany , Brisbane, Australia , Bucharest, Romania , Buenos Aires, Argentina , CABA, Argentina , Calais, France , Calgary, Canada , Ciudad Autonoma de Buenos Aires, Argentina and 43 more locations